The current perspective and opportunities of small nucleic acid-based therapeutics
© 2024 Wiley Periodicals LLC..
Compared to traditional small molecule and antibody drugs, RNA-based drugs offer a simple design, short research and development cycles, high specificity, broad treatment fields, and long-term efficacy. As a result, RNA-based drugs are extensively used to treat genetic diseases, tumors, viral infections, and other illnesses, suggesting that they have the potential to become the third-largest drug class after small molecule and antibody drugs. Currently, more than 10 small nucleic acid drugs have gained regulatory approval. The commercialization successes of small nucleic acid drugs will stimulate the development of RNA-based drugs. Small nucleic acid drugs primarily target liver diseases, metabolic diseases, genetic diseases, and tumors, and there is also significant potential for expanding indications in the future. This review provides a brief overview of the advantages and development of small nucleic acid-based therapeutics and shows a focus on platform technologies such as chemical modifications and delivery systems that have enabled the clinical translation of small nucleic acid-based therapeutics. Additionally, we summarize the latest clinical progress in small nucleic acid-based therapeutics for the treatment of various diseases, including rare diseases, liver diseases, metabolic diseases, and tumors. Finally, we highlight the future prospects for this promising treatment approach.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
Drug development research - 85(2024), 2 vom: 27. Feb., Seite e22164 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Yang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ASO |
|---|
| Anmerkungen: |
Date Completed 28.02.2024 Date Revised 28.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/ddr.22164 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369012593 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369012593 | ||
| 003 | DE-627 | ||
| 005 | 20240229171252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ddr.22164 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM369012593 | ||
| 035 | |a (NLM)38411296 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Yang |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The current perspective and opportunities of small nucleic acid-based therapeutics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2024 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Wiley Periodicals LLC. | ||
| 520 | |a Compared to traditional small molecule and antibody drugs, RNA-based drugs offer a simple design, short research and development cycles, high specificity, broad treatment fields, and long-term efficacy. As a result, RNA-based drugs are extensively used to treat genetic diseases, tumors, viral infections, and other illnesses, suggesting that they have the potential to become the third-largest drug class after small molecule and antibody drugs. Currently, more than 10 small nucleic acid drugs have gained regulatory approval. The commercialization successes of small nucleic acid drugs will stimulate the development of RNA-based drugs. Small nucleic acid drugs primarily target liver diseases, metabolic diseases, genetic diseases, and tumors, and there is also significant potential for expanding indications in the future. This review provides a brief overview of the advantages and development of small nucleic acid-based therapeutics and shows a focus on platform technologies such as chemical modifications and delivery systems that have enabled the clinical translation of small nucleic acid-based therapeutics. Additionally, we summarize the latest clinical progress in small nucleic acid-based therapeutics for the treatment of various diseases, including rare diseases, liver diseases, metabolic diseases, and tumors. Finally, we highlight the future prospects for this promising treatment approach | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ASO | |
| 650 | 4 | |a Patisiran | |
| 650 | 4 | |a RNA therapeutic | |
| 650 | 4 | |a siRNA | |
| 650 | 4 | |a small nucleic acid | |
| 650 | 7 | |a Nucleic Acids |2 NLM | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Li, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Dandan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yuheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Xiaoyan |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Qin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug development research |d 1993 |g 85(2024), 2 vom: 27. Feb., Seite e22164 |w (DE-627)NLM081794991 |x 1098-2299 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2024 |g number:2 |g day:27 |g month:02 |g pages:e22164 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ddr.22164 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2024 |e 2 |b 27 |c 02 |h e22164 | ||